Lymphocytic prolactin does not contribute to systemic lupus erythematosus hyperprolactinemia

Clinical and Experimental Rheumatology

Volumn 28, Issue 6, 2010, Pages 866-872

  Paraiba, D B ^a   Soares, C R J ^a   Bartolini, P ^a   Arthuso, F S ^a   Borba, E F ^b   Bonfa, E ^b   Bronstein, M D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

Bioassays; Hyperprolactinemia; Lupus erythematosus; Prolactin; RT PCR

Indexed keywords

LYMPHOCYTIC PROLACTIN; PROLACTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GEL FILTRATION CHROMATOGRAPHY; GENE EXPRESSION; HORMONE ACTION; HUMAN; HUMAN CELL; HYPERPROLACTINEMIA; IMMUNOFLUORESCENCE; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; CASE CONTROL STUDY; HYPOPHYSIS; IMMUNE SYSTEM; LYMPHOCYTE; METABOLISM; MIDDLE AGED;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERPROLACTINEMIA; IMMUNE SYSTEM; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MALE; MIDDLE AGED; PITUITARY GLAND; PROLACTIN;

EID: 79952646852     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. FREEMAN ME, KANYICSKA B, LERANT A, NAGY G: Prolactin: Structure, Function, and Regulation of Secretion. Physiol Rev 2000; 80: 1523-631.
2. BOLE-FEYSOT C, GOFFIN V, EDERY M, BINART N, KELLY PA: Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19: 225-68.
3. BEN-JONATHAN N, MERSHON JL, ALLEN DL, STEINMETZ RW: Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996; 17: 639-69.
4. WALKER SE, ALLEN SH, MCMURRAY RW: Prolactin and autoimmune disease. Trends Endocrinol Metab 1993; 4: 147-51.
5. ORBACH H, SHOENFELD Y: Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007; 6: 537-42.
6. Chuang E, Molitch ME: Prolactin and autoimmune diseases in humans. Acta Biomed 2007; 78 (Suppl. 1): 255-61.
7. De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A: Prolactin and autoimmunity. Pituitary 2005; 8: 25-30. (Pubitemid 44680082)
8. LAVALLE C, LOYO E, PANIAGUA R et al.: Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol 1987; 14: 268-72.
9. Jara-Quezada L, Graef A, Lavalle C: Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol 1991; 18: 349-53.
10. JARA LJ, PACHECO-REYES H, MEDINA G, ANGELES U, CRUZ-CRUZ P, SAAVEDRA MA: Prolactin levels are associated with lupus activity, lupus anticoagulant, and poor outcome in pregnancy. Ann N Y Acad Sci 2007; 1108: 218-26.
11. FOLOMEEV M, PROKAEVA T, NASSONOVA V, MASENKO E, OVTRAHT N: Prolactin levels in men with SLE and RA. J Rheumatol 1990; 17: 1569-70.
12. PEEVA E, VENKATESH J, MICHAEL D, DIAMOND B: Prolactin as a modulator of B cell function: implications for SLE. Biomed Pharmacother 2004; 58: 310-19.
13. JARA LJ, VERA-LASTRA O, MIRANDA JM, ALCALÁ M, ALVAREZ-NEMEGYEI J: Prolactin in human systemic lupus erythematosus. Lupus 2001; 10: 748-56.
14. VERA-LASTRA O, MENDEZ C, JARA LJ et al.: Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment. J Rheumatol 2003; 30: 2140-6. (Pubitemid 37221842)
15. MOSZKORZOVÁ L, LACINOVÁ Z, MAREK J, MUSILOVÁ L, DOHNALOVÁ A, DOSTÁL C: Hyperprolactinaemia in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2002; 20: 807-12.
16. PASOTO SG, MENDONÇA BB, BONFÁ E: Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 2002; 11: 175-80.
17. PACILIO M, MIGLIARESI S, MELI R, AMBROSONE L, BIGLIARDO B, DI CARLO R: Elevated bioactive prolactin levels in systemic lupus erythematosus - association with disease activity. J Rheumatol 2001; 28: 2216-21.
18. JACOBI AM, ROHDE W, VENTZ M, RIEMEKASTEN G, BURMESTER GR, HIEPE F: Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 2001; 10: 554-61.
19. JARA LJ, LAVALLE C, FRAGA A et al.: Prolactin, immunoregulation, and autoimmune diseases. Semin Arthritis Rheum 1991; 20: 273-84.
20. SHABANOVASS, ANANIEVALP, ALEKBEROVA ZS, GUZOV II: Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26: 436-41.
21. TAN EM, COHEN AS, FRIES JF et al:. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
22. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
23. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
24. VIEIRA JGH, TACHIBANA TT, OBARA LH, MACIEL RMB: Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin Chem 1988; 44: 1758-9.
25. BÖYUM A: Isolation of leucocytes from human blood. Further observations, methylcellulose, dextran, and ficoll as erythrocyte aggregating agents. Scand J Clin Lab Invest Suppl 1968; 97: 31-50.
26. HARRIS R, UKAEJIOFO EO: Tissue typing using a routine one-step Lymphocyte separation procedure. Br J Haematol 1970; 18: 229-35.
27. TANAKA T, SHIU RPC, GOUT PW, BEER CT, NOBLE RL, FRIESEN HG: A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J Clin Endocrinol Metab 1980; 51: 1058-63.
28. BERNICHTEIN S, JEAY S, VAUDRY R, KELLY PA, GOFFIN V: New Homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine 2003; 20: 177-90.
29. Glezer A, Soares CR, Vieira JG et al: Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay, J Clin Endocrinol Metab 2006; 91: 1048-55. (Pubitemid 43357779)
30. CHOMCZYNSKI P, SACCHI N: Single-step method of RNA isolation by acid guanidiniumthiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
31. WACKER MJ, GODARD MP: Analysis of onestep and two-step real-time RTPCR using SuperScript III. J Biomol Tech 2005; 16: 266-71.
32. GIULIETTI A, OVERBERGH L, VALCKX D, DECALLONNE B, BOUILLON R, MATHIEU C: An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001; 25: 386-401.
33. GINZINGER DG: Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream. Exp Hernami 2002; 30: 503-12.
34. LIVAK KJ, SCHMITTGEN TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 2001; 25: 402-8.
35. CRUZ J, AVINÃ-ZUBIETAA, DE LA ESCALERA GM, CLAPP C, LAVALLE C: Molecular heterogeneity of prolactin in the plasma of patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 1331-5.
36. Leaños-Miranda A, Chá Vez-Rueda KA, Blanco-Favela F: Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 866-75.
37. LÉANOS-MIRANDA A, CÁRDENAS-MONDRAGON G, ULLOA-AGUIRRE A, ISORDIASALAS I, PARRA A, RAMfREZ-PEREDO J: Anti-probating autoantibodies in pregnant women with systemic lupus erythematosus: maternal and fetal outcome. Lupus 2007; 16: 342-9.
38. GLEZER A: Human macroprolactin biological activity study in Nb2 cells and in Ba/F-03 cells expressing human long prolactin receptor (thesis). São Paulo, São Paulo, University of São Paulo Medical School 2005, 122p.
39. HATTORI N, IKEKUBO K ISHIHARA T, MORIDERA K, HINO M, KURAHACHI H: Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. Eur J Endocrinol 1994; 130: 438-45.
40. BEN-JONATHAN N, LA PENSEE CR, LA PENSEE EW: What can we learn from rodents about prolactin in humans? Endocr Rev 2008; 29: 1-41.
41. SOARES CR, UEDA EK, OLIVEIRA TL, GOMIDE FI, HELLER SR, BARTOLINI P: Distinct human prolactin (hPRL) and growth hormone (hGH) behavior under bacteriophage lambda PL promoter control: temperature plays a major role in protein yields. J Biotechnol 2008; 133: 27-35.
42. HANDELSMAN DJ, MCDOWELL IF, CATERSON ID, TILLER DJ, HALL BM, TURTLE JR: Testicular function after renal transplantation: comparison of Cyclosporin A with azathioprine and prednisone combination regimes. Clin Nephrol 1984; 22: 144-8.
43. GRZESZCZAK W, KOKOT F, WIECEK A, ZUKOWSKA-SZCZECHOWSKA E: Prolactin secretion in kidney transplant patients. Int Urol Nephrol 1990; 22: 567-71.
44. KAJDANIUK D, MAREK B, KOS-KUDLA B: Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5fluorouracil on plasma melatonin and chosen hormones in breast cancer premenopausal patients. J Clin Pharm Ther 2001; 26: 297-301.
45. KAJDANIUK D, MAREK B: Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma insulin-like growth factor-I and chosen hormones in breast cancer pre-menopausal patients. J Clin Pharm Ther 2000; 25: 67-72.
46. GROSVENOR CE: The release of prolactin in the lactating rat: effect of chloroquine. Neuroendocrinology 1984; 39: 64-7.
47. WALKER SE: Bromocriptine treatment of systemic lupus erythematosus. Lupus 2001; 10: 762-8.
48. MCMURRAY RW, WEIDENSAUL D, ALLEN SH, WALKER SE: Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995; 22: 2084-91.
49. Jara LJ, Cruz-Cruz P, Saavedra MA et al: Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial. Ann N Y Acad Sci 2007; 1110: 297-304. (Pubitemid 350043018)
50. BERWAER M, MARTIAL JA, DAVIS JR: Characterization of an upstream promoter directing extrapituitary expression of human prolactin gene. Mol Endocrinol 1994; 8: 635-42.